✦ LIBER ✦

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

✍ Scribed by David A. Reardon; Annick Desjardins; Katherine B. Peters; James J. Vredenburgh; Sridharan Gururangan; John H. Sampson; Roger E. McLendon; James E. Herndon II; April Coan; Stevie Threatt; Allan H. Friedman; Henry S. Friedman

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 181 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26188

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of carboplatin, irinoteca

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma

✍ David A. Reardon; Annick Desjardins; Katherine B. Peters; Sridharan Gururangan; 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 736 KB

Phase II study of metronomic chemotherap

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

✍ David A. Reardon; Annick Desjardins; Katherine Peters; Sridharan Gururangan; Joh 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 230 KB

Phase 2 study of carboplatin, docetaxel,

Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer

✍ William N. William Jr; Merrill S. Kies; Frank V. Fossella; Diane D. Liu; Gregory 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 183 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB